FGF4 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

164 results for “FGF4”

Trials

View all 120 →

FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

172 participants · First posted Dec 25, 2014

The FGF/FGFR Signalling Pathway:

421 participants · First posted Oct 6, 2017

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

20 participants · First posted Sep 1, 2023

Drugs

View all 28 →

FGFR prodrugs

FGF2 program

FGFR4(Exiris)

News

View all 16 →

Rogaratinib Achieves 41.7% Response Rate in SDH-Deficient GIST, Demonstrating Breakthrough Efficacy for Previously Untreatable Tumor Subtype

Tyra Biosciences' FGFR3 Inhibitor TYRA-300 Shows Promise in Urothelial Cancer

Rogaratinib Plus Atezolizumab Shows Promise in FGFR mRNA-Overexpressing Urothelial Cancer

Page 1 of 17